SVA SINOVAC BIOTECH LTD

BEARISH Impact: 7/10 6-K
Horizon days Filed May 8, 2026 Processed 1mo ago SEC 0001213900-26-054027
Notable filing: 6-K
Latest settled — T+5d
SVA ▲ 0.00% at T+5d
SHORT call ✗ call lost 0.00% · α vs SPY -0.09% · entry $6.47 → $6.47
Next anchor: T+20d due yesterday
Currently $6.47 · +0.00% from $6.47 entry (call sign-flipped)
Entry anchored
May 8, 2026
via day open
T+1d
0.00%
call 0.00% · α -0.14%
$6.47
settled 4w ago
T+5d
0.00%
call 0.00% · α -0.09%
$6.47
settled 26d ago
T+20d
call — · α —
due yesterday
T+60d
call — · α —
in 8w

Price Chart

Loading chart...

Executive Summary

Sinovac reported flat revenue of $130.3M for H1 2025, but swung from a $93.9M profit to a $21.7M net loss, driven by $68.1M in IPR&D/goodwill impairments and reduced investment income. The company also restated prior-period financials and declared a $4.0B special dividend, masking underlying operational weakness.

Actionable Insight

The earnings collapse and restatement signal deteriorating fundamentals despite a high cash balance. Traders should watch for further guidance on the rabies vaccine launch and resolution of the 2018 PIPE share litigation, which could impact the dividend payable and share count.

Key Facts

  • Revenue nearly flat at $130.3M (+1.2% YoY)
  • Net loss attributable to common shareholders of $21.7M vs net income of $93.9M in H1 2024
  • Impairment of $68.1M in IPR&D and goodwill related to rabies vaccine subsidiary
  • Restatement of prior-period financial statements (Non-Reliance on previously issued numbers)
  • Declared a special cash dividend of $55.00 per share totaling $4.0B, with $3.3B paid

Financial Impact

Earnings collapsed from $93.9M net income to $21.7M net loss; impairments totaled $68.1M; special dividend of $4.0B declared

net incomeepsgoodwill

Risk Factors

  • Further impairments from delayed vaccine launches
  • Litigation over 2018 PIPE shares may affect capital structure
  • Restatement raises credibility concerns with investors

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-054027
Document: ea0289810-6k_sinovac.htm0001213900-26-054027
Document: 0001213900-26-054027-index-headers.html0001213900-26-054027
Document: 0001213900-26-054027-index.html0001213900-26-054027
Document: 0001213900-26-054027.txt0001213900-26-054027
4 reports for SVA
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for SVA — sortable, filterable
Type Now
Jun 5, 2026
4d ago
20-F
BEARISH ★ 8/10
$6.47 awaiting T+5awaiting T+5$6.47 (+0.00%)
May 29, 2026
11d ago
6-K
BEARISH ★ 7/10
$6.47 $6.47· 0.00%▼ −2.75%$6.47 (+0.00%)
May 21, 2026
19d ago
6-K
NEUTRAL ★ 2/10
$6.47 $6.47· 0.00%▼ −1.85%$6.47 (−0.00%)
May 8, 2026
4w ago
6-K
BEARISH ★ 7/10
$6.47 $6.47· 0.00%▼ −0.09%$6.47 (+0.00%)
Showing 4 of 4

US Market Status

Market Closed — Opens in 7h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access